Scancell shares were 10% higher in earlier trade on Monday after releasing positive news on their ModiFY trial.
Scancell said their ModiFY trial had received approval from the safety review committee to expand to study after the most cohort of patients presented no safety concern and one patient displayed regression.
Scancell is conducting trials of their Modi-1 therapy for patients with renal or head and neck cancers who are also using checkpoint inhibitors. Scancell will now expand the trial across two further cohorts of 21 people each.
The company has also been permitted to recruit 30 people into the neoadjuvant arm of the Modi-1 trial.
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented:
“This is an important milestone for the Company as we now have approval to treat patients with Modi-1 monotherapy or in combination with a CPI in four different tumour types either pre- or post-tumour resection. The information extracted from this study will be invaluable in defining the patient population that will benefit the most from our cancer vaccine, Modi-1.”
